SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug […]
Drug-Device Combinations
Modular Medical adds insulin delivery tech veteran to board
Modular Medical (Nasdaq:MODD) announced that it appointed industry veteran Jeff Goldberg to its board of directors. Goldberg brings decades of experience in healthcare, life sciences and medical device leadership. His track record includes taking part in the development of generic insulin. Goldberg also began his work in medtech alongside MiniMed founder Alfred E. Mann. “We are […]
Tandem agrees to pay $36M to settle Roche patent litigation
Tandem Diabetes Care (Nasdaq:TNDM) recently filed an SEC Form 8-K announcing its entry into a patent litigation settlement with Roche. The two companies entered into a settlement, mutual release and cross-license agreement. It resolves all actual or potential patent disputes as of May 21. According to the SEC filing, the settlement relates to Tandem’s t:slim […]
Vivani files with SEC to spin off neurostim business, focus on drug delivery implants
Vivani Medical (Nasdaq:VANI) announced today that it filed a Form 10 registration statement with the SEC to spin off its neurostimulation unit. The company said earlier this year that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future […]
Senseonics closes public offering, private placement with Abbott
Senseonics (NYSE:SENS) announced that it closed its previously announced public offering and private placement with Abbott. Last week, the long-term continuous glucose monitor maker said it commenced an underwritten public offering of common stock worth $50 million. At the same time, it entered into a securities purchase agreement with another CGM maker — Abbott. Under […]
Embecta eyes shift from insulin delivery to broader medical supplies focus
Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
Medtronic announced today that it received CE mark for several expanded indications for its Prevail balloon catheter. The expanded indications for the paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (or drug-coated balloon/DCB) cover the treatment of coronary artery disease (CAD). According to the medtech giant, Prevail now has the broadest range of CE mark […]
Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
Sequel Med Tech announced today that it agreed to integrate its twiist automated insulin delivery system with a future Abbott sensor. The companies agreed to pair twiist, powered by Tidepool, with Abbott‘s glucose-ketone sensor, currently under development. Sequel said the agreement aims to improve outcomes for people with type 1 diabetes. It adds ketone sensing capabilities […]
Medtronic to separate Diabetes business unit
Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]
Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K to state that it received CE mark for its Mobi insulin delivery system. San Diego-based Tandem can now market the miniature, durable automated insulin delivery system with Control-IQ+ technology in Europe. According to the filing, the company intends to pursue additional regulatory and pre-commercial activities now. […]
